Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mutations of optineurin in amyotrophic lateral sclerosis

Abstract

Amyotrophic lateral sclerosis (ALS) has its onset in middle age and is a progressive disorder characterized by degeneration of motor neurons of the primary motor cortex, brainstem and spinal cord1. Most cases of ALS are sporadic, but about 10% are familial. Genes known to cause classic familial ALS (FALS) are superoxide dismutase 1 (SOD1)2, ANG encoding angiogenin3, TARDP encoding transactive response (TAR) DNA-binding protein TDP-43 (ref. 4) and fused in sarcoma/translated in liposarcoma (FUS, also known as TLS)5,6. However, these genetic defects occur in only about 20–30% of cases of FALS, and most genes causing FALS are unknown. Here we show that there are mutations in the gene encoding optineurin (OPTN), earlier reported to be a causative gene of primary open-angle glaucoma (POAG)7, in patients with ALS. We found three types of mutation of OPTN: a homozygous deletion of exon 5, a homozygous Q398X nonsense mutation and a heterozygous E478G missense mutation within its ubiquitin-binding domain. Analysis of cell transfection showed that the nonsense and missense mutations of OPTN abolished the inhibition of activation of nuclear factor kappa B (NF-κB), and the E478G mutation revealed a cytoplasmic distribution different from that of the wild type or a POAG mutation. A case with the E478G mutation showed OPTN-immunoreactive cytoplasmic inclusions. Furthermore, TDP-43- or SOD1-positive inclusions of sporadic and SOD1 cases of ALS were also noticeably immunolabelled by anti-OPTN antibodies. Our findings strongly suggest that OPTN is involved in the pathogenesis of ALS. They also indicate that NF-κB inhibitors could be used to treat ALS and that transgenic mice bearing various mutations of OPTN will be relevant in developing new drugs for this disorder.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Exon 5 deletion, nonsense and missense mutations of the OPTN gene.
Figure 2: Influence of OPTN mutations.
Figure 3: Identification of OPTN in distinctive intracytoplasmic inclusions of subjects with ALS.

References

  1. 1

    Leigh, P. N. in Handbook of Clinical Neurology: Amyotrophic Lateral Sclerosis Vol. 82 (eds Eisen, A. A. & Shaw, P. J.) 249–278 (Elsevier, 2007)

    Google Scholar 

  2. 2

    Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62 (1993)

    ADS  CAS  PubMed  Article  Google Scholar 

  3. 3

    Greenway, M. J. et al. ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. Nature Genet. 38, 411–413 (2006)

    CAS  PubMed  Article  Google Scholar 

  4. 4

    Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668–1672 (2008)

    ADS  CAS  PubMed  Article  Google Scholar 

  5. 5

    Kwiatkowski, T. J. et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205–1208 (2009)

    ADS  CAS  PubMed  Article  Google Scholar 

  6. 6

    Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208–1211 (2009)

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7

    Rezaie, T. et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 295, 1077–1079 (2002)

    ADS  CAS  PubMed  Article  Google Scholar 

  8. 8

    Huqun et al. Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am. J. Respir. Crit. Care Med. 175, 263–268 (2007)

    CAS  PubMed  Article  Google Scholar 

  9. 9

    Li, Y., Kang, J. & Horwitz, M. S. Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains. Mol. Cell. Biol. 18, 1601–1610 (1998)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10

    Schwamborn, K., Weil, R., Courtois, G., Whiteside, S. T. & Iaraël, A. Phorbol esters and cytokines regulate the expression of the NEMO-related protein, a molecule involved in a NF-κB-independent pathway. J. Biol. Chem. 275, 22780–22789 (2000)

    CAS  PubMed  Article  Google Scholar 

  11. 11

    Wagner, S. et al. Ubiquitin binding mediates the NF-κB inhibitory potential of ABIN proteins. Oncogene 27, 3739–3745 (2008)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12

    Hattula, K. & Peränen, J. FIP-2, a coiled-coil protein, links hutingtin to Rab8 and modulates cellular morphogenesis. Curr. Biol. 10, 1603–1606 (2000)

    CAS  PubMed  Article  Google Scholar 

  13. 13

    Sahlender, D. A. et al. Optineurin links myosin VI to the Golgi complex and is involved in Golgi organization and exocytosis. J. Cell Biol. 169, 285–295 (2005)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14

    Zhu, G., Wu, C. J. & Ashwell, J. D. Optineurin negatively regulates TNFα-induced NF-κB activation by competing with NEMO for ubiquitinated RIP. Curr. Biol. 17, 1438–1443 (2007)

    CAS  PubMed  Article  Google Scholar 

  15. 15

    De Marco, N., Buono, M., Troise, F. & Diez-Roux, G. Optineurin increases cell survival and translocates to the nucleus in a Rab8-dependent manner upon an apoptotic stimulus. J. Biol. Chem. 281, 16147–16156 (2006)

    CAS  PubMed  Article  Google Scholar 

  16. 16

    Chalasani, M. L., Balasubramanian, D. & Swarup, G. Focus on molecules: optineurin. Exp. Eye Res. 87, 1–2 (2008)

    CAS  PubMed  Article  Google Scholar 

  17. 17

    Iwase, A. et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology 111, 1641–1648 (2004)

    PubMed  Google Scholar 

  18. 18

    Mrowka, R., Blüthgen, N. & Fähling, M. Seed-based systematic discovery of specific transcription factor target genes. FEBS J. 275, 3178–3192 (2008)

    CAS  PubMed  Article  Google Scholar 

  19. 19

    Jiang, Y. M. et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann. Neurol. 57, 236–251 (2005)

    CAS  PubMed  Article  Google Scholar 

  20. 20

    Pizzi, M. & Spano, P. Distinct roles of diverse nuclear factor-κB complexes in neuropathological mechanisms. Eur. J. Pharmacol. 545, 22–28 (2006)

    CAS  PubMed  Article  Google Scholar 

  21. 21

    Toro, D. et al. Mutant huntingtin impairs post-Golgi trafficking to lysozomes by delocalizing optineurin/Rab8 complex from the Golgi apparatus. Mol. Biol. Cell 20, 1478–1492 (2009)

    PubMed  PubMed Central  Article  Google Scholar 

  22. 22

    Takarada, T. et al. A protein–protein interaction of stress-responsive myosin VI endowed to inhibit neural progenitor self-replication with RNA binding protein, TLS, in murine hippocampus. J. Neurochem. 110, 1457–1468 (2009)

    CAS  PubMed  Article  Google Scholar 

  23. 23

    Yoshimura, A. et al. Myosin-Va facilitates the accumulation of mRNA/protein complex in dendritic spines. Curr. Biol. 16, 2345–2351 (2006)

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants-in-aid from the Ministry of Education, Science, and Culture of Japan, by a grant from the Smoking Research Foundation to H. Kawakami, and by the Japan Science and Technology Agency, Core Research for Evolutional Science & Technology to T.T. We thank E. Nakajima for technical support, K. Nakayama, H. W. Shin, M. Omi and H. Nakamura for conducting some of the experiments, and T. Miki and K. Noda for providing some DNA samples and clinical information. This paper is dedicated to the patients and families who contributed to this project.

Author information

Affiliations

Authors

Contributions

Author Contributions H. Kawakami designed and supervised the study. H.Mo. and K.H. extracted candidate genes. H.Ma. and M.K. performed sequencing analysis. H.Ma., H.Mo., Y.W., T.T., S.M., H. Kawakami and H.S. conducted molecular biological analysis. H.I., Y.K., H. Ku., H. Kato, K.O. and A.H. performed pathological analysis and provided pathological samples. Y.I., H.N., R.K., O.K., N.M., K.A., A.K., T.H, T.K., M.A., N.S. and K.K. collected clinical information and samples. H. Kawakami, H.Ma., H.I. and K.H. wrote the paper.

Corresponding author

Correspondence to Hideshi Kawakami.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

This file contains Supplementary Tables 2 and 4, Supplementary Figures 1-9 with legends, Supplementary Patient Information and Supplementary Notes and References. (PDF 7299 kb)

Supplementary Table 1

This file contains the SNP typing of subjects 1, 2, 3 and 4. (PDF 253 kb)

Supplementary Table 3

This file contains the SNP typing of subjects 5, 6, 7 and 8. (PDF 641 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Maruyama, H., Morino, H., Ito, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223–226 (2010). https://doi.org/10.1038/nature08971

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing